Literature DB >> 28397397

The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.

N C Leksa1, P-L Chiu2, G M Bou-Assaf1, C Quan1, Z Liu1, A B Goodman1, M G Chambers2, S E Tsutakawa3, M Hammel3, R T Peters1, T Walz1,4, J D Kulman1.   

Abstract

Essentials Recombinant factor VIII (rFVIII) Fc fusion protein has a 1.5-fold longer half-life than rFVIII. Five orthogonal methods were used to characterize the structure of rFVIIIFc compared to rFVIII. The C-terminal Fc fusion does not perturb the structure of FVIII in rFVIIIFc. The FVIII and Fc components of rFVIIIFc are flexibly tethered and functionally independent.
SUMMARY: Background Fusion of the human IgG1 Fc domain to the C-terminal C2 domain of B-domain-deleted (BDD) factor VIII (FVIII) results in the recombinant FVIII Fc (rFVIIIFc) fusion protein, which has a 1.5-fold longer half-life in humans. Objective To assess the structural properties of rFVIIIFc by comparing its constituent FVIII and Fc elements with their respective isolated components, and evaluating their structural independence within rFVIIIFc. Methods rFVIIIFc and its isolated FVIII and Fc components were compared by the use of hydrogen-deuterium exchange mass spectrometry (HDX-MS). The structure of rFVIIIFc was also evaluated by the use of X-ray crystallography, small-angle X-ray scattering (SAXS), and electron microscopy (EM). The degree of steric interference by the appended Fc domain was assessed by EM and surface plasmon resonance (SPR). Results HDX-MS analysis of rFVIIIFc revealed that fusion caused no structural perturbations in FVIII or Fc. The rFVIIIFc crystal structure showed that the FVIII component is indistinguishable from published BDD FVIII structures. The Fc domain was not observed, indicating high mobility. SAXS analysis was consistent with an ensemble of rigid-body models in which the Fc domain exists in a largely extended orientation relative to FVIII. Binding of Fab fragments of anti-C2 domain antibodies to BDD FVIII was visualized by EM, and the affinities of the corresponding intact antibodies for BDD FVIII and rFVIIIFc were comparable by SPR analysis. Conclusions The FVIII and Fc components of rFVIIIFc are structurally indistinguishable from their isolated constituents, and show a high degree of structural independence, consistent with the functional comparability of rFVIIIFc and unmodified FVIII.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  B-domain-deleted factor VIII; bleeding; factor VIII; hemophilia A; rFVIIIFc protein

Mesh:

Substances:

Year:  2017        PMID: 28397397      PMCID: PMC5500164          DOI: 10.1111/jth.13700

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  55 in total

1.  EMAN: semiautomated software for high-resolution single-particle reconstructions.

Authors:  S J Ludtke; P R Baldwin; W Chiu
Journal:  J Struct Biol       Date:  1999-12-01       Impact factor: 2.867

2.  The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.

Authors:  Damian Houde; Steven A Berkowitz; John R Engen
Journal:  J Pharm Sci       Date:  2010-12-29       Impact factor: 3.534

3.  A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.

Authors:  M Shima; D Scandella; A Yoshioka; H Nakai; I Tanaka; S Kamisue; S Terada; H Fukui
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

6.  A role for the C2 domain of factor VIII in binding to von Willebrand factor.

Authors:  E L Saenko; M Shima; K J Rajalakshmi; D Scandella
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

7.  Application of a novel affinity adsorbent for the capture and purification of recombinant factor VIII compounds.

Authors:  Justin T McCue; Keith Selvitelli; Joshua Walker
Journal:  J Chromatogr A       Date:  2009-09-23       Impact factor: 4.759

8.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Authors:  Johnny Mahlangu; Jerry S Powell; Margaret V Ragni; Pratima Chowdary; Neil C Josephson; Ingrid Pabinger; Hideji Hanabusa; Naresh Gupta; Roshni Kulkarni; Patrick Fogarty; David Perry; Amy Shapiro; K John Pasi; Shashikant Apte; Ivan Nestorov; Haiyan Jiang; Shuanglian Li; Srividya Neelakantan; Lynda M Cristiano; Jaya Goyal; Jurg M Sommer; Jennifer A Dumont; Nigel Dodd; Karen Nugent; Gloria Vigliani; Alvin Luk; Aoife Brennan; Glenn F Pierce
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

Review 9.  Validation of macromolecular flexibility in solution by small-angle X-ray scattering (SAXS).

Authors:  Michal Hammel
Journal:  Eur Biophys J       Date:  2012-05-26       Impact factor: 1.733

10.  Negative Staining and Image Classification - Powerful Tools in Modern Electron Microscopy.

Authors:  Melanie Ohi; Ying Li; Yifan Cheng; Thomas Walz
Journal:  Biol Proced Online       Date:  2004-03-19       Impact factor: 3.244

View more
  4 in total

1.  Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A.

Authors:  Martin Rodriguez; Christopher D Porada; Graҫa Almeida-Porada
Journal:  Curr Stem Cell Rep       Date:  2019-11-20

Review 2.  Evolving SAXS versatility: solution X-ray scattering for macromolecular architecture, functional landscapes, and integrative structural biology.

Authors:  Chris A Brosey; John A Tainer
Journal:  Curr Opin Struct Biol       Date:  2019-06-13       Impact factor: 6.809

Review 3.  Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors:  Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal:  Eur J Haematol       Date:  2021-03-31       Impact factor: 2.997

4.  Genetic and Bioinformatic Strategies to Improve Diagnosis in Three Inherited Bleeding Disorders in Bogotá, Colombia.

Authors:  Juliana Lago; Helena Groot; Diego Navas; Paula Lago; María Gamboa; Dayana Calderón; Diana C Polanía-Villanueva
Journal:  Genes (Basel)       Date:  2021-11-18       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.